Prostate Cancer Clinical Trial
Official title:
A Randomized Phase II Study Comparing Intensity Modulated External Beam Radiation Therapy (IMRT) Versus Permanent Interstitial Prostate Brachytherapy (PIPB) for Low Risk and Low-tier Intermediate Risk Prostate Cancer
Purpose:
The purpose of this trial is to compare two different treatment options for patients with low
risk and low-tier intermediate risk prostate cancer. The two treatment arms being compared in
this study are: (control arm) permanent interstitial prostate brachytherapy (PIPB) VERSUS
(experimental arm) intensity modulated external beam radiation therapy (IMRT).
Hypothesis:
The acute and late toxicities experienced by patients in the experimental arm (IMRT) are not
significantly worse then the toxicities experienced by patients in the control arm (PIPB).
Justification:
Patients with low risk and low-tier intermediate risk prostate cancer have a number of
different standard treatment options to chose from that include a radical prostatectomy,
conventional external beam radiotherapy (EBRT), or permanent interstitial prostate
brachytherapy (PIPB). Each of these treatment options have good outcomes, although they are
known to have a small risk of complications associated with each of them. Unfortunately,
these treatment options have never been directly compared and therefore it is difficult to
determine how these treatment options compare with respect to overall outcomes and toxicity.
A recent analysis from the BC Cancer Agency suggested that patients treated with conventional
EBRT within the Agency had inferior outcomes compared to PIPB. This data, as well as other
indirect evidence, suggest that conventional EBRT may be a suboptimal treatment option
compared to PIPB. Intensity modulated external beam radiotherapy (IMRT) is a new technology
that allows for the delivery of high doses of radiation that tightly conforms to the target
and limits the dose to surrounding critical structures. Although IMRT is currently a standard
therapeutic option that is utilized in other cancer sites at the BC Cancer Agency, it has not
been utilized in prostate cancer yet. Recent evidence has confirmed that this experimental
therapy is able to allow for the safe escalation of dose for prostate cancer patients, which
may lead to improved outcomes, without increasing toxicity. There is no current evidence that
side effects and complication risks associated with IMRT are associated with any serious risk
of increased toxicity, although this continues to be studied.
This study will compare this new therapeutic approach (IMRT) directly with a standard
treatment option for prostate cancer patients (PIPB). This trial will allow us to determine
how the toxicities of these treatments compare with each other and, if successful, will
potentially lead to a larger study which will analyse how the outcomes of these therapeutic
interventions compare. We hope that this trial will make an important contribution to the
care and future management of patients with prostate cancer.
Objectives:
Primary Objective:
The primary end point of this study is the acute and late toxicities of the therapeutic
interventions.
Secondary Objectives:
This trial is also intended to determine:
- The willingness of eligible patients to be randomized to the treatment interventions.
- Obstacles to accrual that need to be addressed.
- Testing our ability to meet accrual targets.
- Checking quality assurance benchmarks for IMRT and PIPB procedures.
- Discovering and relieving bottlenecks in IMRT planning and procedures.
- Quality of life.
- Pathological local control.
- Biochemical relapse-free survival.
- Metastasis-free survival.
- Overall survival.
Research Method:
The patients will be randomly assigned with equal probability to one of two treatment arms:
Arm 1 (Control Arm) - Permanent interstitial prostate brachytherapy (PIPB). Arm 2
(Experimental Arm) - Intensity modulated external beam radiation therapy (IMRT).
Statistical Analysis:
Primary Endpoints:
Acute GI grade 3 or higher toxicity. Acute GU grade 3 or higher toxicity. Late GI grade 3 or
higher toxicity. Late GU grade 3 or higher toxicity.
Secondary Endpoints:
All acute and late toxicities. Quality of life scores (Using the expanded prostate cancer
index composite - EPIC).
Pathological local control. Biochemical relapse-free survival (using Phoenix definition).
Metastasis-free survival. Overall survival.
Planned sample size: 50 patients in total (i.e. 25 patients in each treatment arm).
Statistical analysis:
The two groups will be compared with respect to their primary and secondary endpoints.
Appropriate statistical analysis using a student t test for a statistical difference in crude
rates of grade 3 or higher toxicity between the two treatment arms will be performed. All
endpoints will be analysed for crude event rates with 95% confidence intervals for each
group.
With a sample size of only 50 patients, this trial is not powered to detect differences in
the incidence of common self-limited side effects and adverse reactions compared to standard
therapy. For this reason, the trial's limited power is augmented by a Trial Safety Committee
(TSC) which is bound by rules that require suspension/ termination of trial accrual in the
event of major complications (See Section 8.3 of Data Monitoring - Human Ethics Application
for Clinical Study or Part I: Section 5.3 on page 11 of the protocol).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |